Literature DB >> 24706814

Whole-exome sequencing reveals LRP5 mutations and canonical Wnt signaling associated with hepatic cystogenesis.

Wybrich R Cnossen1, René H M te Morsche, Alexander Hoischen, Christian Gilissen, Melissa Chrispijn, Hanka Venselaar, Soufi Mehdi, Carsten Bergmann, Joris A Veltman, Joost P H Drenth.   

Abstract

Polycystic livers are seen in the rare inherited disorder isolated polycystic liver disease (PCLD) and are recognized as the most common extrarenal manifestation in autosomal dominant polycystic kidney disease. Hepatic cystogenesis is characterized by progressive proliferation of cholangiocytes, ultimately causing hepatomegaly. Genetically, polycystic liver disease is a heterogeneous disorder with incomplete penetrance and caused by mutations in PRKCSH, SEC63, PKD1, or PKD2. Genome-wide SNP typing and Sanger sequencing revealed no pathogenic variants in hitherto genes in an extended PCLD family. We performed whole-exome sequencing of DNA samples from two members. A heterozygous variant c.3562C > T located at a highly conserved amino acid position (p.R1188W) in the low density lipoprotein receptor-related protein 5 (LRP5) gene segregated with the disease (logarithm of odds score, 4.62) but was not observed in more than 1,000 unaffected individuals. Screening of LRP5 in a PCLD cohort identified three additional mutations in three unrelated families with polycystic livers (p.V454M, p.R1529S, and p.D1551N), again all undetected in controls. All variants were predicted to be damaging with profound structural effects on LRP5 protein domains. Liver cyst tissue and normal hepatic tissue samples from patients and controls showed abundant LRP5 expression by immunohistochemistry. Functional activity analyses indicated that mutant LRP5 led to reduced wingless signal activation. In conclusion, we demonstrate that germ-line LRP5 missense mutations are associated with hepatic cystogenesis. The findings presented in this study link the pathophysiology of PCLD to deregulation of the canonical wingless signaling pathway.

Entities:  

Keywords:  gene identification; β-catenin pathway

Mesh:

Substances:

Year:  2014        PMID: 24706814      PMCID: PMC3986119          DOI: 10.1073/pnas.1309438111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Expression of the type I diabetes-associated gene LRP5 in macrophages, vitamin A system cells, and the Islets of Langerhans suggests multiple potential roles in diabetes.

Authors:  D J Figueroa; J F Hess; B Ky; S D Brown; V Sandig; A Hermanowski-Vosatka; R C Twells; J A Todd; C P Austin
Journal:  J Histochem Cytochem       Date:  2000-10       Impact factor: 2.479

2.  LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.

Authors:  Y Gong; R B Slee; N Fukai; G Rawadi; S Roman-Roman; A M Reginato; H Wang; T Cundy; F H Glorieux; D Lev; M Zacharin; K Oexle; J Marcelino; W Suwairi; S Heeger; G Sabatakos; S Apte; W N Adkins; J Allgrove; M Arslan-Kirchner; J A Batch; P Beighton; G C Black; R G Boles; L M Boon; C Borrone; H G Brunner; G F Carle; B Dallapiccola; A De Paepe; B Floege; M L Halfhide; B Hall; R C Hennekam; T Hirose; A Jans; H Jüppner; C A Kim; K Keppler-Noreuil; A Kohlschuetter; D LaCombe; M Lambert; E Lemyre; T Letteboer; L Peltonen; R S Ramesar; M Romanengo; H Somer; E Steichen-Gersdorf; B Steinmann; B Sullivan; A Superti-Furga; W Swoboda; M J van den Boogaard; W Van Hul; M Vikkula; M Votruba; B Zabel; T Garcia; R Baron; B R Olsen; M L Warman
Journal:  Cell       Date:  2001-11-16       Impact factor: 41.582

3.  A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait.

Authors:  Randall D Little; John P Carulli; Richard G Del Mastro; Josée Dupuis; Mark Osborne; Colleen Folz; Susan P Manning; Pamela M Swain; Shan-Chuan Zhao; Brenda Eustace; Michelle M Lappe; Lia Spitzer; Susan Zweier; Karen Braunschweiger; Youssef Benchekroun; Xintong Hu; Ronald Adair; Linda Chee; Michael G FitzGerald; Craig Tulig; Anthony Caruso; Nia Tzellas; Alicia Bawa; Barbara Franklin; Shannon McGuire; Xavier Nogues; Gordon Gong; Kristina M Allen; Anthony Anisowicz; Arturo J Morales; Peter T Lomedico; Susan M Recker; Paul Van Eerdewegh; Robert R Recker; Mark L Johnson
Journal:  Am J Hum Genet       Date:  2001-12-03       Impact factor: 11.025

4.  Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the beta-catenin gene.

Authors:  S Saadi-Kheddouci; D Berrebi; B Romagnolo; F Cluzeaud; M Peuchmaur; A Kahn; A Vandewalle; C Perret
Journal:  Oncogene       Date:  2001-09-20       Impact factor: 9.867

5.  Identification of a locus for autosomal dominant polycystic liver disease, on chromosome 19p13.2-13.1.

Authors:  D M Reynolds; C T Falk; A Li; B F King; P S Kamath; J Huston; C Shub; D M Iglesias; R S Martin; Y Pirson; V E Torres; S Somlo
Journal:  Am J Hum Genet       Date:  2000-10-23       Impact factor: 11.025

6.  High bone density due to a mutation in LDL-receptor-related protein 5.

Authors:  Lynn M Boyden; Junhao Mao; Joseph Belsky; Lyle Mitzner; Anita Farhi; Mary A Mitnick; Dianqing Wu; Karl Insogna; Richard P Lifton
Journal:  N Engl J Med       Date:  2002-05-16       Impact factor: 91.245

7.  Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.

Authors:  Melissa Chrispijn; Tom J G Gevers; Jeroen C Hol; Rene Monshouwer; Heleen M Dekker; Joost P H Drenth
Journal:  J Hepatol       Date:  2013-03-14       Impact factor: 25.083

8.  Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density.

Authors:  Liesbeth Van Wesenbeeck; Erna Cleiren; Jeppe Gram; Rodney K Beals; Olivier Bénichou; Domenico Scopelliti; Lyndon Key; Tara Renton; Cindy Bartels; Yaoqin Gong; Matthew L Warman; Marie-Christine De Vernejoul; Jens Bollerslev; Wim Van Hul
Journal:  Am J Hum Genet       Date:  2003-02-10       Impact factor: 11.025

9.  Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease.

Authors:  Airong Li; Sonia Davila; Laszlo Furu; Qi Qian; Xin Tian; Patrick S Kamath; Bernard F King; Vicente E Torres; Stefan Somlo
Journal:  Am J Hum Genet       Date:  2003-01-15       Impact factor: 11.025

10.  Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion.

Authors:  Takahiro Fujino; Hiroshi Asaba; Man-Jong Kang; Yukio Ikeda; Hideyuki Sone; Shinji Takada; Dong-Ho Kim; Ryoichi X Ioka; Masao Ono; Hiroko Tomoyori; Minoru Okubo; Toshio Murase; Akihisa Kamataki; Joji Yamamoto; Kenta Magoori; Sadao Takahashi; Yoshiharu Miyamoto; Hisashi Oishi; Masato Nose; Mitsuyo Okazaki; Shinichi Usui; Katsumi Imaizumi; Masashi Yanagisawa; Juro Sakai; Tokuo T Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-30       Impact factor: 11.205

View more
  34 in total

1.  LDL Receptor-Related Protein 6 Modulates Ret Proto-Oncogene Signaling in Renal Development and Cystic Dysplasia.

Authors:  Yongping Wang; Arjun Stokes; Zhijian Duan; Jordan Hui; Ying Xu; YiPing Chen; Hong-Wu Chen; Kit Lam; Chengji J Zhou
Journal:  J Am Soc Nephrol       Date:  2015-06-05       Impact factor: 10.121

Review 2.  Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.

Authors:  Luca Fabris; Romina Fiorotto; Carlo Spirli; Massimiliano Cadamuro; Valeria Mariotti; Maria J Perugorria; Jesus M Banales; Mario Strazzabosco
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08       Impact factor: 46.802

3.  Genetics: Novel causative genes for polycystic liver disease.

Authors:  María J Perugorria; Jesús M Banales
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-05-31       Impact factor: 46.802

4.  Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.

Authors:  Tom J G Gevers; Frederik Nevens; Vicente E Torres; Marie C Hogan; Joost P H Drenth
Journal:  Liver Int       Date:  2015-11-09       Impact factor: 5.828

Review 5.  Polycystic liver diseases: advanced insights into the molecular mechanisms.

Authors:  Maria J Perugorria; Tatyana V Masyuk; Jose J Marin; Marco Marzioni; Luis Bujanda; Nicholas F LaRusso; Jesus M Banales
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-09-30       Impact factor: 46.802

6.  Increased YAP Activation Is Associated With Hepatic Cyst Epithelial Cell Proliferation in ARPKD/CHF.

Authors:  Lu Jiang; Lina Sun; Genea Edwards; Michael Manley; Darren P Wallace; Seth Septer; Chirag Manohar; Michele T Pritchard; Udayan Apte
Journal:  Gene Expr       Date:  2017-09-15

7.  LRP5 variants may contribute to ADPKD.

Authors:  Wybrich R Cnossen; René H M te Morsche; Alexander Hoischen; Christian Gilissen; Hanka Venselaar; Soufi Mehdi; Carsten Bergmann; Monique Losekoot; Martijn H Breuning; Dorien J M Peters; Joris A Veltman; Joost P H Drenth
Journal:  Eur J Hum Genet       Date:  2015-04-29       Impact factor: 4.246

Review 8.  Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases.

Authors:  Emilie Cornec-Le Gall; Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2017-10-16       Impact factor: 10.121

9.  Polycystic liver disease: The interplay of genes causative for hepatic and renal cystogenesis.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Hepatology       Date:  2018-04-19       Impact factor: 17.425

Review 10.  Therapeutic Targets in Polycystic Liver Disease.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.